Celcuity (CELC) is back in focus after fresh clinical data showed its lead drug candidate, gedatolisib, delivered longer progression-free survival and higher response rates in both HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer.
Despite the encouraging trial updates, Celcuity’s share price has had a choppy run, with the 7 day share price return up 5.06%, the 90 day share price return down 25.26%, and the year to date share price return down 31.25%. However, the 3 year total shareholder return is very large at roughly 7x that period’s starting level, which hints that recent weakness follows a long and powerful earlier rerating.
Spot opportunities related to Celcuity's clinical momentum by scanning a curated set of 19 high quality undiscovered gems with strong fundamentals that may still be flying under most investors' radar.After a sharp pullback but with a market cap near US$3.4b, Celcuity now trades at a steep discount to both analyst targets and intrinsic value estimates. Is the price or the valuation work out of line?
Most Popular Narrative: 57.1% Undervalued
On the most followed narrative, Celcuity’s fair value sits at $161.09, well above the last close of $69.13, which puts a lot of weight on gedatolisib turning clinical momentum into future cash flows.
Celcuity is investing heavily ahead of potential approval, with third quarter 2025 net loss of US$43.8m, net cash used in operating activities of US$44.8m and higher research, development and general and administrative expenses tied to launch preparation and expanded headcount. If revenue does not ramp as planned, the combination of ongoing losses and increased debt, including the US$500m term loan facility and 2.75% convertible notes, could pressure future earnings and net margins.
See why 5 investors see Celcuity as 57% undervalued.
Result: Fair Value of $161.09 (UNDERVALUED)
Still, the narrative could crack if key gedatolisib trials disappoint or if regulators demand extra data, which would delay Celcuity’s path to potential revenue.
Find out about the key risks to this Celcuity narrative.
Next Steps
Sentiment on Celcuity is split, with meaningful upside implied by fair value estimates but clear trial and financing questions still hanging over the story. Act quickly. Review the full spread of signals and weigh both sides through 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Celcuity?
If you want to stress test your Celcuity view and widen your opportunity set, line up a few contrasting stock ideas in minutes.
- Upgrade your watchlist with resilient businesses by zeroing in on a 29 resilient stocks with low risk scores that aim to keep volatility and risk scores in check.
- Hunt for mispriced quality by scanning a focused group of 36 high quality undervalued stocks that combine solid fundamentals with potentially appealing entry points.
- Strengthen your defensive side by building a shortlist from a 5 dividend fortresses that may offer 5%+ yields alongside an emphasis on stability.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com